A new economic study says popular GLP-1 drugs do more than shrink waistlines—they cut serious sick leave for workers by about one‑sixth and could quietly reshape the workplace.
Story Snapshot
- Researchers found a 17.3% drop in long-term sick leave after workers started GLP-1 treatment.
- Long-term sick leave here means medically certified absences of more than 30 days.
- The study estimates fiscal gains equal to about 1.3–1.5% of a worker’s yearly income.
- Early evidence suggests fewer sick days and fewer hospital visits, but drug costs still raise hard questions.
Study claims GLP-1 treatment cuts serious sick leave by 17%
Researchers from universities in Copenhagen, Chicago, and Duke dug into nationwide Danish health and employment records to see how GLP-1 drugs affect the labor market. They focused on workers starting drugs such as semaglutide, which are used for type 2 diabetes and weight loss.
The headline result is blunt: GLP‑1 treatment reduced long‑term sickness leave by 17.3% over four years compared with similar patients who had not yet started the drugs.
Long‑term sick leave in this paper means illness-related absences that last more than 30 days and must be medically certified. Before starting GLP‑1 therapy, the average worker in the study spent about 5.5% of time on long‑term sick leave.
After treatment, that share dropped by about 0.95 percentage points, which is where the 17.3% reduction figure comes from. This is not about a random sick day with a head cold. It is about serious health issues that keep people out for weeks.
The effect grows over time and comes with fiscal upside
The study does not show a quick hit that fades away. The reduction in long-term sick leave deepened as time on the drug increased.
In the first two years after patients started GLP‑1 treatment, the drop in long‑term sick leave was around 0.8 percentage points, growing to about 1.1 percentage points in years three and four.
Researchers then translated those fewer sick days into money. Using Danish earnings data, they estimated fiscal benefits equal to roughly 1.3–1.5% of annual labor income per employed individual on GLP‑1 therapy.
In dollar terms, that works out to about 866 United States dollars per treated worker per year. That figure reflects less time on publicly funded sick-leave benefits and stronger attachment to work.
Broader health gains support the sick-leave results
The labor-market paper lines up with a wider wave of research showing that GLP‑1 medicines cut serious health risks, especially for people with obesity and diabetes. Trials and reviews now connect these drugs to lower rates of stroke, heart failure, heart attack, kidney disease, sleep apnea, and more.
If you reduce the diseases that knock people out of the workforce, you would expect fewer long work absences. The Danish study’s findings fit that story and add hard numbers on workplace impact.
Other work points the same way. A weight management program in the United Kingdom that combined GLP‑1 use with digital support saw sick‑leave days fall by 45%, and long‑term sick leave of five days or more drop by 56% after nine months.
Consulting firms tracking employer medical costs report slower cost growth among employees using GLP‑1s for diabetes and weight loss compared with non‑users. None of this proves magic, but it does show a consistent pattern: better metabolic health tends to pay off at work.
Costs, coverage, and conservative questions about value
The 17% reduction in long-term sick leave sounds like an obvious win for employers and taxpayers, but the math gets more complicated when drug prices enter the picture.
A cost‑benefit review found that GLP‑1 therapy reduced medical costs by about $ 560 per user per year, yet average annual drug costs were roughly $ 6,540 per user. That gap leaves the short‑term return on investment negative for many employers, especially smaller firms watching every dollar.
Employers also are not required to cover these drugs for weight loss in most of the United States. Federal law does not force health plans to pay for GLP‑1s for obesity, and only one state, North Dakota, has moved to require coverage for certain weight‑related uses.
Surveys show that fewer than one in five large employers cover GLP‑1s mainly for weight loss, though coverage is more common among the very largest firms. That means many workers who could gain from fewer sick days may not have access through their job.
What the study shows—and what it does not
The Danish paper uses strong national data and finds a clear association between GLP‑1 treatment and less long‑term sick leave. For policy debates, that matters.
The findings suggest that when workers with obesity or diabetes gain steady access to GLP‑1s, they are more likely to stay on the job and less likely to rely on long sickness benefits. For Americans who value personal responsibility and lower dependency on government programs, that is a notable point.
GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI
— CBS News (@CBSNews) July 22, 2026
Yet the study does not settle every question. It relies on observational data, not a randomized workplace experiment, so other factors could play a role even though the researchers use careful methods to compare similar groups. Employers weighing coverage still must balance freedom of choice, fiscal discipline, and long‑term health outcomes.
In this case, GLP‑1 drugs look like a powerful tool that can cut serious sick leave and improve productivity, but they are not a free lunch, and the real test will be whether markets and policy can bring costs down without losing those gains.
Sources:
cbsnews.com, meltemdaysal.com, inc.com, pmc.ncbi.nlm.nih.gov, workcare.com, docs.iza.org, sentinelgroup.com
